Company intelligence / Profile preview

Shenzhen Cell Valley

Shenzhen, Guangdong, China

Ownership: Private
Development stage: Other

Overview

Shenzhen Cell Valley operates as a major CDMO and CRO in the cell and gene therapy (CGT) sector, providing industrial-scale GMP production for retroviral and lentiviral vectors. It supports several clinical-stage programs for partners, including the first approved CAR-T therapy in China (Akilencel).

Therapeutic areas: OncologyCardiovascularImmunologyNeurology
Modalities: CAR-T cell therapyCAR-NK cell therapyCAR-M cell therapyT cell receptor engineered T cell therapyTIL therapyGene therapyCell therapyExosome-based therapyOncolytic virus therapyStem cell therapyViral vectorMonoclonal antibody
Industry: Contract Research Organization

Partnerships

Fosun KiteJW TherapeuticsInnoCare PharmaHengrui PharmaceuticalsBioGendLu Daopei Medical GroupGaobo Medical Group

Beyond the preview

Go deeper on Shenzhen Cell Valley.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenzhen Cell Valley.

Explore the full profile